The earnings transcript for Amgen Inc. presents several key points that could influence the short-term stock performance:

1. **Positive Repatha Outcomes**: The positive results from the Repatha cardiovascular outcomes trial (FOURIER) are a significant milestone, validating the efficacy and safety of PCSK9 inhibition in cardiovascular disease. This is likely to enhance the product's market positioning and potential for broader reimbursement.

2. **Guidance and Financial Performance**: Amgen reported strong financial results for 2016, with revenue growth, improved operating margins, and significant free cash flow generation. However, the 2017 guidance reflects challenges such as biosimilar competition, limited net selling price growth, and foreign exchange headwinds. Despite these, the company remains confident in its long-term growth strategy.

3. **Pipeline and New Launches**: Amgen's pipeline is robust, with several promising candidates in late-stage development, including Parsabiv, EVENITY, Erenumab, and biosimilars. These launches are expected to drive future growth.

4. **Regulatory and Political Environment**: The company's interactions with the Trump administration suggest a supportive environment for innovation and potential tax reforms. However, there is also awareness of drug pricing pressures and the need for market-based reforms.

Given these points:

- The positive Repatha outcomes and the robust pipeline are likely to be well-received by investors, indicating potential for short-term stock growth.
- The guidance and financial performance, although tempered by some challenges, still reflect a strong underlying business and confidence in long-term growth.

### Conclusion:
The overall tone of the earnings call is positive, driven by significant clinical trial results, a strong pipeline, and a favorable regulatory environment. This suggests a positive short-term impact on the stock price.

### Rating:
1